Crinetics Pharmaceuticals Management
Management criteria checks 3/4
Crinetics Pharmaceuticals' CEO is R. Struthers, appointed in Dec 2008, has a tenure of 15.33 years. total yearly compensation is $5.60M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 1.31% of the company’s shares, worth $44.24M. The average tenure of the management team and the board of directors is 2.8 years and 3.6 years respectively.
Key information
R. Struthers
Chief executive officer
US$5.6m
Total compensation
| CEO salary percentage | 10.5% |
| CEO tenure | 15.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27
Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Compensation vs Market: R.'s total compensation ($USD5.60M) is about average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
CEO
R. Struthers (61 yo)
15.3yrs
Tenure
US$5,602,127
Compensation
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.3yrs | US$5.60m | 1.31% $ 44.2m | |
| Founder & Chief Scientific Officer | 2.5yrs | US$2.08m | 0.056% $ 1.9m | |
| Chief Financial Officer | 6.3yrs | US$2.31m | 0.073% $ 2.5m | |
| Chief Commercial Officer | 2.2yrs | US$2.84m | 0.0023% $ 76.3k | |
| Chief Development Officer | 1.6yrs | US$3.61m | 0.0018% $ 61.1k | |
| Chief Operating Officer | 2.6yrs | US$2.98m | 0.0064% $ 215.7k | |
| General Counsel & Corporate Secretary | 2.8yrs | no data | no data | |
| Chief Human Resources Officer | 3.9yrs | no data | no data | |
| Chief Medical Officer | 5.8yrs | US$1.55m | 0.017% $ 564.1k | |
| Head of Intellectual Property | no data | no data | no data | |
| Chief Business Officer | 2.1yrs | no data | no data | |
| Vice President of Clinical Endocrinology | 3.4yrs | no data | no data |
2.8yrs
Average Tenure
57yo
Average Age
Experienced Management: CRNX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.4yrs | US$5.60m | 1.31% $ 44.2m | |
| Independent Chairman of the Board | 8.5yrs | US$316.40k | 0.13% $ 4.3m | |
| Independent Director | 6.2yrs | US$293.40k | 0.016% $ 543.2k | |
| Independent Director | 3.6yrs | US$277.40k | no data | |
| Independent Director | 2.3yrs | US$879.80k | 0.0064% $ 216.7k | |
| Independent Director | 6.2yrs | US$279.90k | no data | |
| Independent Director | 4.8yrs | US$289.40k | 0.0077% $ 259.9k | |
| Independent Director | 2.1yrs | US$769.98k | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data |
3.6yrs
Average Tenure
60yo
Average Age
Experienced Board: CRNX's board of directors are considered experienced (3.6 years average tenure).